Methods and apparatus to reduce anxiety using mixed reality are disclosed herein. An example method of reducing anxiety in a person during a blood collection process includes providing a mixed reality headset to a person prior to collecting blood from the person. The method includes initiating a mixed reality program on the mixed reality headset. The mixed reality program causes a display device to display a mixed reality environment with one or more virtual objects on glasses of the headset, determines a gaze direction of the eyes of the person, and causes a change in one or more of the virtual objects in the mixed reality environment based on the gaze direction. The method further includes collecting blood from the person while the person is exposed to the mixed reality program.
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
A61B 3/113 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/16 - Dispositifs pour la psychotechnie; Test des temps de réaction
A61M 21/00 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose
2.
HUMAN MILK OLIGOSACCHARIDES FOR ENHANCING BLOOD-BRAIN BARRIER FUNCTION
A nutritional composition for use in enhancing one or more features or functions of the blood-brain barrier, including promoting healing or improved function of the blood-brain barrier. In certain embodiments, a method comprises administering to an individual in need thereof a nutritional composition comprises at least one human milk oligosaccharide as described herein to treat or prevent one or more blood-brain barrier related conditions.
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p.ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
A61K 31/702 - Oligosaccharides, c. à. d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
3.
BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY
Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
4.
HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS
Provided herein are compositions, systems, and methods for assessing and monitoring disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to hepatitis B virus infection.
The invention provides methods for determining whether a subject suspected of having a myocardial infarction is experiencing a Type I or Type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on decision tree based algorithms to process a subject's sex, age, and cardiac troponin concentration(s) and subject's galectin-3 (Gal-3) concentration.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p.ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present disclosure relates to materials and methods for amplifying and detecting monkeypox virus in a sample, comprising a variety of combinations of amplification oligonucleotides and oligonucleotide probes. The disclosure also relates to oligonucleotide sequences, kits, and methods for detecting monkeypox virus.
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
A method of promoting healthy catch-up growth in a pediatric individual comprises administering a nutritional composition with an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric individual during a period of weight gain. A method also provides promoting healthy catch-up growth in an underweight individual by administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the individual.
Disclosed herein are methods and systems for determining whether at least one indeterminate pulmonary nodule identified in a subject is likely to be malignant or likely not to be malignant.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
9.
BOVINE MILK EXOSOMES FOR DELIVERING VITAMIN K2 AND INCREASING BIOAVAILABILITY
Bovine milk exosomes are loaded with vitamin K2. Nutritional compositions comprise the vitamin K2-loaded bovine milk exosomes and at least one of protein, fat and carbohydrate. A method for manufacturing vitamin K2-loaded bovine milk exosomes comprises mixing an aqueous solution of bovine milk exosomes with solubilized vitamin K2. A method of preparing a nutritional composition for providing improved bioavailability of vitamin K2 in vivo comprises adding bovine milk exosomes loaded with vitamin K2 to an aqueous solution which is added to a nutritional composition. A method also provides enhancing vitamin K2 bioavailability in vivo in a subject.
Disclosed herein are systems and assays that employ magnetically susceptible beads and point-of-care devices comprising magnetic immunosensors to determine the amount of glial fibrillary acidic protein (GFAP) in a biological sample obtained from a subject.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
11.
RECLOSABLE PLASTIC BOTTLE WITH WAIST AND STRENGTHENING RIB(S)
The present disclosure is directed to a bottle made of polyethylene terephthalate (PET) and having a circular cross-section. The bottle has a sidewall spanning between a neck finish and a base. The sidewall includes a shoulder portion and a panel portion, with the lower end of the shoulder portion and the upper end of the panel portion each sloping inward to create a waist. One or more circumferential ribs are positioned within the waist, and preferably at the trough of the waist. The one or more circumferential ribs are designed and configured to increase the hoop strength of the bottle, the vacuum stability of the bottle, or both.
Bifidobacterium animalisLactisLactis CECT 8145 (BPL1) and a carbohydrate blend to the individual. The carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch. A nutritional composition comprises protein, fat, the carbohydrate blend, and BPL1.
A method of increasing insulin sensitivity in a subject in need thereof comprises administering a nutritional composition comprising inositol, lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A nutritional composition comprises from about 0.01 to about 15 wt % HMB, from about 0.03 to about 40 wt % lysine, from about 0.02 to about 30 wt % arginine, and from about 0.01 to about 20 wt % inositol, all based on the weight of the nutritional composition.
A23L 29/00 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement
A23L 29/30 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement contenant des hydrolysats d'amidon, p.ex. de la dextrine
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A heat-treated, powdered nutritional composition comprises protein, fat, carbohydrate, and about 0.001 to about 5 wt % hesperidin, based on the weight of the powdered nutritional composition, wherein the weight ratio of (2S)-hesperidin to (2R)-hesperidin in the powdered nutritional composition is at least about 4:1. A process for manufacturing a heat-treated, powdered nutritional composition comprising hesperidin comprises providing an emulsified liquid nutritional composition comprising protein, fat, carbohydrate, and hesperidin, heat treating the emulsified liquid nutritional composition at a temperature of at least about 70ºC and not greater than about 105ºC for about 1 to about 30 seconds, and spray-drying the heat-treated liquid nutritional composition to form the powdered nutritional composition.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
15.
NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND BOVINE IMMUNOGLOBULIN
Disclosed are methods for treating or preventing infections in an individual and nutritional compositions for administering to individuals for the purpose of treating and/or preventing infections. The nutritional compositions include a combination of a human milk oligosaccharide and a protein ingredient having an enriched amount of one or more bovine immunoglobulin(s).
C07K 16/06 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
LATERAL FLOW METHODS, ASSAYS, AND DEVICES FOR DETECTING THE PRESENCE OR MEASURING THE AMOUNT OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 AND/OR GLIAL FIBRILLARY ACIDIC PROTEIN IN A SAMPLE
Disclosed herein are methods and devices for performing at least one lateral flow assay on a biological sample obtained from a subject to determine an amount or presence of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) alone, or an amount or presence of UCH-L1 and an amount or presence of glial fibrillary acidic protein (GFAP).
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
17.
BETA-HYDROXY BETA-METHYLBUTYRATE AND A CITRUS FLAVONOID FOR PROMOTING MUSCLE REGENERATION
A method for promoting muscle regeneration in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p.ex. médicaments traditionnels à base de plantes
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
19.
SYSTEMS AND METHODS FOR DETERMINING UCH-L1, GFAP, AND OTHER BIOMARKERS IN BLOOD SAMPLES
Disclosed herein are systems and methods for determining ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof in a blood sample obtained from a subject. Also disclosed herein are systems and methods for determining CK-MB, β-hCG, thyroid stimulating hormone (TSH), homocysteine, free thyroxine (free T4) or any combinations thereof in a blood sample.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B32B 7/00 - Produits stratifiés caractérisés par la relation entre les couches; Produits stratifiés caractérisés par l’orientation relative des éléments caractéristiques entre les couches, ou par les valeurs relatives d’un paramètre mesurable entre les couches, c. à d. produits comprenant des couches ayant des propriétés physiqu; Produits stratifiés caractérisés par la jonction entre les couches
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Sample analysis systems and methods using assay surfaces, assay processing units (APUs), assay processing systems (APSs), and laboratory systems are disclosed. An assay surface includes a sample processing component comprising a plurality of regions, including at least one wash region and at least one storage region configured to hold a plurality of solid supports moveable through the regions under a magnetic force, and a detection component configured to receive the solid supports. An APU includes an assay surface receiving component, a magnetic element configured to generate a moveable magnetic field, and one or more processors configured to move the magnetic field. An APS includes one or more assay surfaces and an APU. A laboratory system includes one or more APSs and a controller for parallel processing. Sample processing and detection methods are disclosed with a reduced sample volume and/or shortened processing time and/or higher sensitivity.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
22.
METHODS AND COMPOSITIONS FOR IMPROVING INSULIN PRODUCTION AND SECRETION
A method of improving insulin production in a subject suffering from impaired β-cell function comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject. A method of restoring and/or preserving β-cell mass in a subject suffering from impaired insulin production comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject. A method of delaying diabetes progression in a subject suffering from impaired insulin production comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.
Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
25.
METHODS FOR DETECTING IMMUNOGLOBULIN G, SUBCLASS 4 (IGG4) IN A BIOLOGICAL SAMPLE
Disclosed herein are methods, kits, and systems for detecting or determining an amount, quantity, concentration and/or level of immunoglobulin G, subclass 4 (IgG4) in a biological sample from a subject. Particularly, the methods, kits and systems are directed to detection of IgG4 using an anti-IgG4 antibody that does not cross-react with other IgG subclasses.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
26.
METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING
A nutritional composition comprises HMB, arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes. A method for improving wound healing in a subject comprises administering beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method for improving wound healing in a subject comprises administering a nutritional composition comprising HMB, arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes.
Provided herein are methods and nutritional compositions for treating gas in an individual. The nutritional compositions are useful for treating gas in an individual and include a mixture of human milk oligosaccharides and a probiotic blend of Bifidobacterium lactis, Bifidobacterium infantis, and Streptococcus thermophilus.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
28.
METHODS OF DIAGNOSING OR AIDING IN DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, AN OVER PRESSURIZATION WAVE, AND/OR BLAST WIND
Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI) by detecting levels of a biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject (e.g., a human subject) that has or may have sustained an injury or suspected injury to the head that is caused or believed to have been caused by acoustic energy, electromagnetic energy (e.g., from a sonic weapon, a directed energy weapon or a combination thereof), an over pressurization wave, blast wind, or any combination thereof.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
29.
METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT
Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
30.
SYSTEMS AND METHODS FOR POOLING SAMPLES FOR HIGH-THROUGHPUT ANALYSIS
Systems and methods for onboard pooling of samples for high-throughput analysis of the samples. Including a sample loading area for receiving a plurality of sample tubes, and a sample transport configured to continually transport individual vessels along a transport path from a sample dispense position to a sample capture and transfer position, with intermediate positions therebetween. At least one pipettor to transfer a first and second samples from the sample loading area to the sample transport and to pool the first sample and the second sample in a vessel on the sample transport to form a pooled sample. A sample transfer mechanism to capture at least a fractionated portion of the pooled sample from the vessel at the sample capture and transfer position and to transfer the at least a fractionated portion of the pooled sample for high-throughput analysis.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
31.
HIGH THROUGHPUT NUCLEIC ACID TESTING OF BIOLOGICAL SAMPLES
The presently disclosed subject matter relates to methods for rapid, sensitive, and high-throughput nucleic acid testing of biological samples, e.g., blood, serum, or plasma samples from donors, as well as systems capable of performing such high-throughput nucleic acid testing.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
32.
METHODS AND COMPOSITIONS FOR IMPROVING MUSCLE STRENGTH AND/OR REDUCING MUSCLE LOSS
A method for improving muscle strength and/or reducing muscle loss in a subject in need thereof comprises administering at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO, and optionally beta-hydroxy-beta-methylbutyrate (HMB) and optionally a plant flavonoid, to the subject. A nutritional composition comprises HMB and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, and, optionally, a plant flavonoid.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p.ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
Liquid nutritional compositions comprise at least about 125 mg/ml of a protein system comprising, based on the weight of the protein system, less than 40 wt % micellar casein, greater than 15 wt % non-micellar casein, whey protein, whey protein hydrolysate, and partially hydrolyzed collagen. The liquid nutritional compositions further comprise at least about 5 mg/ml of β-hydroxy β-methylbutyrate (HMB), fat, and carbohydrate. The liquid nutritional compositions have a zero shear rate viscosity greater than 100 cp, an infinite shear rate viscosity of less than 200 cp, and a ratio of zero shear rate viscosity to infinite shear rate viscosity of greater than about 1.5.
A method for promoting wound healing in a subject comprises administering beta-hydroxy- beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO to the subject in need thereof. A nutritional composition comprises HMB, arginine, glutamine, and an HMO selected from the group consisting of an acidic HMO and a neutral HMO.
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
35.
NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND A DESIGNED LIPID COMPONENT FOR IMPROVING LUNG FUNCTION
Disclosed are methods of and nutritional compositions for treating or improving at least one marker of lung health in an individual. The nutritional compositions include a combination of a human milk oligosaccharide component and a designed lipid component.
A method of improving insulin production in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A method of improving insulin secretion in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and HMB to the subject. A nutritional composition comprises about 0.01 to about 15 wt % HMB, about 0.03 to about 40 wt % lysine, and about 0.02 to about 30 wt % arginine.
Systems, apparatuses and methods may provide technology that identifies minority class data and majority class data in patient-level data, wherein the minority class data corresponds to patients with a health failure and the majority class data corresponds to patients without the health failure, oversamples the minority class data to obtain synthetic class data and automatically reduces, via a machine learning classifier, a set of risk factor variables based on the majority class data, the minority class data and the synthetic class data.
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
Disclosed are methods for treating or preventing infections in an individual and nutritional compositions for administering to individuals for the purpose of treating and/or preventing infections. The nutritional compositions include a combination of a human milk oligosaccharide and a bovine immunoglobulin.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A method of for improving muscle energy production and/or muscle strength in a subject, and/or for reducing muscle loss in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject. A nutritional composition comprises protein, fat, carbohydrate, HMB, and at least one citrus flavonoid.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
40.
SEQUENCE CONVERSION AND SIGNAL AMPLIFIER DNA HAVING ABASIC NUCLEIC ACIDS, AND DETECTION METHODS USING SAME
Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide that includes, in the 5' to 3' direction, a signal DNA generation sequence, an endonuclease recognition site, and a complementary sequence that has at least one abasic moiety and wherein the complementary sequence has a first complementary sequence that is complementary to at least a portion of the signal DNA generation sequence and a second complementary sequence that is complementary to the 3' end of the target nucleic acid. Also disclosed are methods that include a second oligonucleotide including, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide and that optionally has at least one abasic site.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
41.
METHODS FOR ENHANCING MUSCLE PERFORMANCE OR REDUCING CHRONIC FATIGUE BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES
A method of enhancing muscle performance in a subject in need of improved physical performance comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method of reducing chronic fatigue in a subject recovering or recovered from a viral infection comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.
A23C 21/00 - Petit-lait; Préparations à base de petit-lait
A23J 1/20 - Préparation des compositions à base de protéines pour l'alimentation; Ouverture des œufs par grandes quantités et séparation du jaune du blanc à partir du petit-lait
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
42.
METHOD FOR IMPROVING JOINT HEALTH BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES
A method of improving joint health in a subject in need thereof comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof.
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
43.
IMPROVED METHODS, REAGENTS AND KITS FOR DETERGENT-BASED INACTIVATION OF BETACORONAVIRUS PRIOR TO AND/OR WHILE ASSESSING A BIOLOGICAL SAMPLE FOR SARS-COV-2 ANTIGEN OR ANTIBODY
Disclosed herein are methods of inactivating any ß-coronaviruses (e.g., SARS-CoV or SARS-CoV-2) in a biological sample prior to testing the sample for the presence of a ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) antigen or antibody, which involves maintaining the sample in a medium comprising at least one non-ionic surfactant. The at least one non-ionic surfactant inactivates the ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) as determined by an inability of the ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) to replicate in culture.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
44.
METHODS FOR DETERMINING SARS-COV-2 ANTIGEN AND ANTI-SARS-COV-2 ANTIBODY IN A SAMPLE
Disclosed herein are methods, kits, and systems for detecting at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody in a subject, which comprises the use of at least two different types of microparticle reagents for binding at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody and at least two different types of detection reagents for binding each of the microparticle reagents.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
45.
USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
46.
LIQUID NUTRITIONAL COMPOSITIONS WITH WATER-INSOLUBLE PLANT FLAVONOID AND METHOD OF PRODUCTION THEREOF
A method of forming a heat-treated liquid nutritional composition having a neutral pH and comprising a water-insoluble plant flavonoid comprises providing an aqueous liquid nutritional composition having a pH of from about 6 to about 7.5 and comprising protein, fat, carbohydrate, and water-insoluble plant flavonoid, homogenizing the liquid nutritional composition at a pressure of at least about 2000 psi, and heat treating the liquid nutritional composition. A heat-treated liquid nutritional composition having a pH of from about 6 to about 7.5 comprises a water-insoluble plant flavonoid, protein, fat and carbohydrate. At least about 75 wt % of the water-insoluble plant flavonoid remains suspended throughout the liquid nutritional composition after two months of storage at room temperature.
A method of increasing height in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of promoting linear bone growth in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of obtaining an exosome-enriched product from cheese whey comprises subjecting the cheese whey to microfiltration (MF), ultrafiltration (UF), and diafiltration (DF) steps, wherein the MF, UF, and DF steps employ, successively, membranes with cut off values which gradually decrease in size with each filtration step, wherein the cheese whey is sweet cheese whey and has a pH from about 6.0 to about 6.5.
A23C 9/142 - Préparations à base de lait; Lait en poudre ou préparations à base de lait en poudre dans lesquelles la composition chimique du lait est modifiée par des traitements non chimiques par dialyse, osmose inverse ou ultrafiltration
A23L 33/115 - Acides gras ou leurs dérivés; Graisses ou huiles
A23L 33/10 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p.ex. rachitisme, maladie de Paget
A container (100) having a main body (104) including one or more sidewalls (106) having an interior surface (120) and an exterior surface (122) and defining an interior compartment (108), the one or more sidewalls having an upper portion (114) defining a circular opening (110) to the interior compartment and an annular flange (128) extending from the exterior surface and a lid-collar assembly (112, 116) comprising a lid (116) attached to a collar (112) affixed to the main body, the collar having an inner side surface (162) positioned radially outward of the annular flange and a plurality of longitudinally extending ribs (210) spaced apart on the inner side surface, wherein the plurality of ribs engage the annular flange to resist rotation of the lid-collar assembly relative to the main body.
Disclosed herein are methods, kits, and systems relates for detecting the presence or determining the amount of SARS-CoV-2 nucleocapsid protein in one or more samples obtained from a subject.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
51.
METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE
A method of preventing, reducing, or delaying the onset of fatty liver disease in a subject comprises enterally administering intact bovine milk-derived exosomes consisting of endogenous cargo to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the intact bovine milk-derived exosomes consisting of endogenous cargo can be administered in an amount effective to reduce de novo lipogenesis in the subject. The intact bovine milk-derived exosomes consisting of endogenous cargo can be administered to the subject directly or in a nutritional composition.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
52.
METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE
A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the at least one HMO is administered in an amount effective to reduce de novo lipogenesis in the subject. The at least one HMO can be administered to the subject directly or in a nutritional composition.
A61K 31/702 - Oligosaccharides, c. à. d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61L 33/12 - Polypeptides, protéines ou leurs dérivés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
Digital pass verification systems and methods are disclosed herein. An example non-transitory computer readable medium includes instructions that, when executed, cause a processor to at least: verify a flight reservation of a person; check a test record of the person associated with the flight reservation, the test record associated with a diagnostic test for an analyte of interest; and display a first interface when the test record indicates the person tested negative for the analyte of interest and display a second interface when the test record indicates the person tested positive for the analyte of interest.
H04W 12/30 - Sécurité des dispositifs mobiles; Sécurité des applications mobiles
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G16H 10/65 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients stockées sur des supports d’enregistrement portables, p.ex. des cartes à puce, des étiquettes d’identification radio-fréquence [RFID] ou des CD
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p.ex. de la grippe
At least a portion of fabrics (404) for use in medical devices (10, 100, 2000) is formed from polymeric materials. The fabrics may be uncoated, partially coated or fully coated with one or more layers (402) of a polymer. The fabrics may be used for the leaflets (108) and/or cuffs (106) of prosthetic heart valves (100) and as a component of other medical devices (2000).
A stabilized fabric composed of a mesh or a woven fabric is disclosed as are methods of their manufacture, the manufacture of medical devices made using a stabilized fibers and stabilized medical devices are all disclosed. Fabrics can be stabilized by several techniques including: using mechanical, chemical and/or energetic fasteners at warp and weft intersections in the weave; by using various weaving techniques and fibers. Meshes can be stabilized when properly dimensioned and arranged junctions and struts of the necessary properties are used. All of these stabilized fabrics can be made of synthetic polymer materials such as ultrahigh molecular weight PE or PP and expanded PTFE.
A23L 29/30 - Aliments ou produits alimentaires contenant des additifs; Leur préparation ou leur traitement contenant des hydrolysats d'amidon, p.ex. de la dextrine
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
A23G 9/04 - Production de desserts glacés, p.ex. de glaces
A61P 3/14 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes de l'homéostase du calcium
Sample analysis systems and methods using assay surfaces, assay processing units (APUs), assay processing systems (APSs), and laboratory systems are disclosed. An assay surface includes a sample processing component comprising a plurality of regions, including at least one wash region and at least one storage region configured to hold a plurality of solid supports moveable through the regions under a magnetic force, and a detection component configured to receive the solid supports. An APU includes an assay surface receiving component, a magnetic element configured to generate a moveable magnetic field, and one or more processors configured to move the magnetic field. An APS includes one or more assay surfaces and an APU. A laboratory system includes one or more APSs and a controller for parallel processing. Sample processing and detection methods are disclosed with a reduced sample volume and/or shortened processing time and/or higher sensitivity.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
58.
METHODS OF DECREASING MUSCLE ATROPHY AND/OR PROMOTING MUSCLE REGENERATION
Methods of decreasing muscle atrophy and/or promoting muscle regeneration in a subject at risk of muscle atrophy comprise orally administering a nutritional composition comprising at least one of protein, fat and carbohydrate, and bovine milk-isolated exosomes comprising intact exosomes. In specific embodiments, the subject suffers from malnutrition, acquired immune deficiency syndrome (AIDS), cancer, diabetes, chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), non-alcoholic fatty liver disease (NAFLD), or a burn injury, or has undergone clinical corticosteroid treatment.
A23K 10/28 - Produits alimentaires pour animaux à base de matières d’origine animale à base de matières résiduelles, p.ex. de plumes, d'os ou de peau à base de produits laitiers résiduels
A23J 1/20 - Préparation des compositions à base de protéines pour l'alimentation; Ouverture des œufs par grandes quantités et séparation du jaune du blanc à partir du petit-lait
Methods of increasing microvascular blood flow in the muscle of a human subject comprise orally administering about 100 to about 800 mg cocoa flavanols per day in a nutritional composition comprising at least one source of protein, to a subject in need of increased microvascular blood flow in the muscle.
Disclosed herein are methods, complexes, kits, systems and algorithms for detecting or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as, for example, an anti-SARS-CoV antibody or anti-SARS-CoV-2 antibody (including an IgA, IgG and/or an IgM antibody), in one or more samples obtained from a subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
61.
METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-Β-CORONAVIRUS ANTIBODY IN A SAMPLE
Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of β-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject. The methods, kits systems, algorithms and improvements can also be used to monitor a subject's response and/or treatment to a β-coronavirus, determine whether or not a subject will develop or experience a cytokine storm, predict outcome in a subject, determine whether a subject can be administered a vaccine for a β-coronavirus, monitoring antibody response in individuals that have received a β-coronavirus vaccine (such as a SARS-CoV-2 vaccine), and/or determine the immune status of a subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
62.
NUTRITIONAL FORMULATIONS FOR MODULATING RESPIRATORY-INDUCED CYTOKINES
Disclosed are compositions, including nutritional compositions, for reducing illness/infection related symptoms. In particular, administration of the inventive compositions helps to reduce symptoms such as those selected from impaired cognition, fever, anhedonia, loss of appetite, hyperalgesia, and sleep disturbances, lethargy, chills, irritability, and skin hypersensitivity to touch that often result from respiratory virus-induced inflammation.
A method of obtaining an exosome-enriched product comprises providing a whey-containing bovine milk fraction, conducting a first centrifugation of the whey-containing bovine milk fraction to obtain a whey middle fraction, conducting a second centrifugation of the whey middle fraction at an increased speed to obtain a concentrated whey fraction, filtering the concentrated whey fraction to obtain a filtered whey fraction, and conducting a third centrifugation of the filtered whey fraction at a further increased speed to obtain an exosome-enriched product. The exosome-enriched product comprises intact exosomes and less than 5 wt% casein based on the total weight of protein in the exosome-enriched product. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes provided by addition of the exosome-enriched product. A method of improving insulin sensitivity in a subject comprises administering a nutritional composition comprising the exosome-enriched product.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
KATHOLIEKE UNIVERSITEIT LEUVEN KU LEUVEN RESEARCH & DEVELOPMENT (Belgique)
Inventeur(s)
Leirs, Karen
Pérez-Ruiz, Elena
Lammertyn, Jeroen
Abrégé
Provided herein is a method of loading wells with a liquid droplet, or a portion thereof, wherein each liquid droplet comprises solid supports and a detergent or surfactant, such that the detergent or surfactant reduces the contact angle between the liquid droplet and the wells. Also provided is a method of detecting and quantifying an analyte of interest in a sample, which involves loading wells in an array with a liquid droplet according to aforementioned method, wherein the liquid droplet comprises an analyte captured on a solid support.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
65.
METHODS OF TREATING DIARRHEA OR INFLAMMATORY CONDITIONS OF THE GUT
A method of treating diarrhea or an inflammatory condition of the gut in a subject comprises administering a therapeutically effective amount of beta-hydroxy-beta-methylbutyrate (HMB) or a salt thereof to a subject in need thereof. A method of treating secretory diarrhea in a subject comprises administering a therapeutically effective amount of HMB or a salt thereof to a subject exhibiting one or more of the following symptoms: loss of fluids from the gut, loss of electrolytes from the gut, dehydration, or inflammation of the intestinal tract.
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p.ex. de fibres diététiques
A61K 31/702 - Oligosaccharides, c. à. d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
Provided herein are compositions, methods, and kits for amplifying and detecting human bunyaviruses. In certain embodiments, provided herein are bunyavirus specific nucleic acid probes and primers, and methods for detecting bunyavirus nucleic acid.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
68.
COMPOSITIONS AND METHODS FOR DETECTING PICOBIRNAVIRUS
Provided herein are compositions, methods, and kits for detecting human picobirnavirus (PBV). In certain embodiments, provided herein are PBV specific nucleic acid probes and primers, and methods for detecting PBV nucleic acid.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
69.
NUTRITIONAL COMPOSITIONS FOR TREATING A CLOSTRIDIUM DIFFICILE INFECTION
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
A23L 33/21 - Adjonction de substances essentiellement non digestibles, p.ex. de fibres diététiques
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
A61K 31/702 - Oligosaccharides, c. à. d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/718 - Amidon ou amidon dégradé, p.ex. amylose, amylopectine
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
70.
BOVINE MILK-ISOLATED POWDERED EXOSOMES, NUTRITIONAL COMPOSITIONS AND METHODS
Bovine milk-isolated powdered exosomes comprise intact exosomes. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes isolated from bovine milk. A method of preparing powdered exosomes comprises centrifuging bovine milk to form a lipid fraction top layer, a whey fraction middle layer, and a first pellet of cells and debris, separating the whey fraction and centrifuging the separated whey fraction to remove additional fat, casein aggregates and debris and form a substantially clear whey fraction, microfiltering the substantially clear whey fraction to remove residual debris, centrifuging the microfiltered whey fraction to obtain a pellet containing exosomes, incubating the exosome-containing pellet in aqueous medium to dissolve the pellet without disrupting exosome membranes to provide an exosome suspension, and drying the suspension to obtain the powdered exosomes. Methods of lowering a risk of developing, or treating, insulin resistance, prediabetes, or diabetes in a subject employ exosomes isolated from bovine milk.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
At least a portion of sheet materials (400) for use in medical devices (10, 100, 2000) is formed from polymeric materials. The sheet materials may be partially coated or fully coated with one or more additional layers (402, 404) of a polymer. The sheet materials may be used for the leaflets (108) and/or cuffs (106) of prosthetic heart valves and as a component of other medical devices.
in vivo in vivo sensor. The protein switch can be used to determine a level of an analyte that is diagnostic for health and/or well-being of a subject.
A plastic container (10) having an upper portion (16) including a reclosable and resealable open top end (18), a base portion (24) closing off an end of the container, and an intermediate portion (22) being integrally formed with and exiting from the upper portion to the base portion. The intermediate portion includes by a plurality of horizontal ribs (42) arranged substantially perpendicular to a longitudinal axis of the container, at least one of the horizontal ribs being disposed longitudinally between an upper land and a lower land. The container has a volume capacity is 235 ml. or greater and a plastic weight of 20 g or less. At least one of the plurality of horizontal ribs has a horizontal rib depth (DR) of at least 4.5 mm and a horizontal rib width (WR) to horizontal rib depth ratio of between 2.2 to 2.7.
Plant-based nutritional compositions comprise fava bean protein isolate and pea protein. The fava bean protein isolate comprises greater than about 10 wt% of the total protein in the composition, and the pea protein comprises less than about 50 wt% of the total protein in the composition. In certain embodiments, the nutritional compositions are high in protein, high in fiber, and low in calories. The compositions may be dairy-free and/or soy-free.
Processes for preparing a powdered nutritional composition comprise dry blending protein, fat, and carbohydrate, micronizing the resultant mixture to provide 99% of particles with a size less than about 50 micrometers, and agglomerating the micronized powder to form agglomerates. Powdered nutritional compositions are produced by the processes of dry blending, micronizing, and agglomerating.
The disclosure provides kits and methods for detecting a substance that interferes with detection of an analyte in a sample and for expanding the dynamic range and reducing the hook effect of an immunoassay. The kits and methods employ two conjugates with two different detectable labels, at least one of which is a chemiluminescent compound of Formula (I).
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
Disclosed herein are compounds, conjugates, and methods that may be used to detect the presence of an analyte in a sample, such as a biological sample.
C09B 23/04 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH un seul groupe CH, p.ex. cyanines, isocyanines, pseudocyanines
C09B 23/06 - Colorants méthiniques ou polyméthiniques, p.ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH trois groupes CH, p.ex. carbocyanines
C09B 57/10 - Complexes métalliques de composés organiques qui ne sont pas des colorants sous la forme non complexée
C09K 11/07 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes ayant des constituants réagissant chimiquement entre eux, p.ex. compositions chimi-luminescentes réactives
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
78.
NUTRITIONAL INGREDIENT WITH FLOW AND ANTIFOAM PROPERTIES
A nutritional ingredient for use in nutritional powders is provided. The nutritional ingredient is an agglomerated calcium source, which includes particles of a calcium source adhered together with a lecithin binder. The nutritional ingredient functions as both a flow agent and an antifoam agent when incorporated into nutritional powders, such as powdered infant formulas.
System for storing and dispensing liquid in a digital microfluidic chip includes a plurality of reservoir electrodes defining a reservoir having an outlet and a first end opposite the outlet, the reservoir configured to be in fluidic communication with at least one device electrode proximate the outlet, the at least one device electrode and at least one of the plurality of reservoir electrodes configured to generate electrical actuation forces to dispense at least one droplet from the reservoir through the outlet. The plurality of reservoir electrodes include a first reservoir electrode proximate the first end, a reservoir outlet electrode proximate the outlet, and at least one intermediate reservoir electrode disposed between the first electrode and the reservoir outlet electrode. The first reservoir electrode, the reservoir outlet electrode, and the at least one intermediate reservoir electrode each has an electrode surface area in plan view greater than or equal to an electrode surface area of each of the at least one device electrodes.
Digital microfluidic device includes a first substrate and a second substrate aligned generally parallel to each other with a gap defined therebetween in side view. At least one of the first substrate and the second substrate include a first electrode array, a second electrode array spaced from and in electrical communication with the first electrode array, and a first interstitial area defined between the first electrode array and the second electrode array. At least one of the first electrode array and the second electrode array is configured to generate electrical actuation forces within an actuation area to urge at least one droplet within the gap along the at least one of the first substrate and the second substrate. At least one spacer is disposed in the first interstitial area to maintain the gap between the first substrate and the second substrate.
Digital microfluidic and analyte detection device includes a first substrate and a second substrate aligned generally parallel to each other with a gap defined therebetween in side view. At least one of the first and second substrates has an electrode array configured to generate electrical actuation forces to urge at least one droplet within the gap along the at least one of the first substrate and the second substrate. The electrode array has a plurality of electrodes defining an electrode array area in plan view. At least one of the first substrate and the second substrate has a well array defining a well array area in plan view. The well array area is bounded within the electrode array area and overlapping a portion of each of the plurality of electrodes. The well array area overlaps less than 75% of the electrode array area in plan view.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
B01L 9/00 - Dispositifs de support; Dispositifs de serrage
82.
EVALUATING BIOMARKERS ALONG WITH ADVANCED MAGNETIC RESONANCE IMAGING PROCEDURES IN A HUMAN SUBJECT THAT HAS SUSTAINED OR MAY HAVE SUSTAINED A HEAD INJURY
Disclosed herein are methods that aid in the determination of whether to perform one or more advanced magnetic resonance imaging (MRI) procedures for a head injury by determining the presence or amount of one or more biomarkers in a sample obtained from the human subject. Also disclosed are methods of aiding in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, e.g., by assessing biomarker levels in combination with advanced MRI procedures. Further, also disclosed are methods of predicting or aiding in the prediction of the outcome of human subjects that have suffered a traumatic brain injury (TBI) as well as determining the course of treatment or efficacy of a course of treatment for a human subject who has suffered a TBI, e.g., by assessing biomarker levels in combination with advanced MRI procedures.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p.ex. angiographie à écoulement contrasté
83.
METHODS FOR PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH CORONARY ARTERY DISEASE
The present disclosure relates to methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on comparing the concentration or levels of cardiac troponin I (cTnI) determined by one or more assays before a stress test and then during or after a stress test.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
84.
DIRECT DETECTION OF SINGLE MOLECULES ON MICROPARTICLES
The disclosure provides methods of analyzing an analyte of interest in a biological sample using fluorescent agents and macroconjugates which comprise a core containing a cross-linked polymer or protein, tags, specific binding members or fragments thereof, and optionally carrier proteins. Also provided are methods of analyzing two or more analytes of interest in a biological sample in a single assay using microparticles and detection conjugates comprising different fluorophore labels, acquiring transmitted light and fluorescent images of the microparticles, and using a customized image analysis process to analyze the acquired images.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
At least a portion of fabrics for use in medical devices is formed from polymeric materials. The fabrics may be uncoated, partially coated or fully coated with one or more layers of a polymer. The fabrics may be used for the leaflets and/or cuffs of prosthetic heart valves and as a component of other medical devices.
A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.
The disclosure provides a method for an enhanced detection of an analyte present in a biological sample. After the formation of the analyte/specific binding member(s)/detectable label complex, the labels are eluted and a first aliquot of eluant is brought into contact with a solid support, wherein the solid support comprises immobilized thereto specific binding member that specifically binds to the label, removing the first aliquot from the solid support and contacting the solid support with a second aliquot of the eluted label, and repeating the above steps, such that the label is concentrated on the solid support for further analysis to quantify the analyte in the biological sample.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
88.
HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS
Provided herein are compositions, systems, and methods for assessing and monitory disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to disease therapies (e.g., in HBV infection).
G01N 33/576 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour l'hépatite
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A package (5) is disclosed for holding a powdered material. The package (5) comprises a container (10) and a scoop (50). The container (10) comprises a main body (20), a first hinged closure (30), and a second hinged closure (40). The main body (20) may optionally comprise a collar (325). The first hinged closure (30) is configured to fully cover and resealably close the main body (20) of the container (10) when the container (10) is not in use. The first hinged closure (30) may comprise a pocket (33) to receive the bowl (52) of the scoop (50). Alternatively, the second hinged closure (40) may comprise a scoop receiving structure (344) to secure a scoop (50). The second hinged closure (40) covers at least a portion of the first hinged closure (30) when the container (10) is not in use, thereby keeping the scoop (50) clean between uses.
A nutritional powder composition comprises from about 0.1 to about 3.0 wt % beta-hydroxy-beta-methylbutyrate (HMB), and from about 10 to about 25 wt % of a protein system, based on the weight of the powder composition. The protein system comprises from about 20 to about 60 wt % sodium caseinate, from 0 to about 30 wt % whey protein, from about 5 to about 25 wt % intact soy protein, and from about 15 to about 60 wt % hydrolyzed soy protein, based on the weight of the protein system. All or a portion of the sodium caseinate in the protein system may be replaced with potassium caseinate, and/or all or a portion of the intact soy protein may be replaced with intact pea protein, and/or all or a portion of the hydrolyzed soy protein may be replaced with hydrolyzed pea protein.
Aqueous lipid emulsions for providing enteral nutrition are provided. The aqueous lipid emulsions include at least 33% of lipids, lipid soluble nutrients, or a combination thereof, based upon the total weight of the emulsion, and are essentially free of carbohydrate and protein. The aqueous lipid emulsions are shelf-stable for at least 7 months. The aqueous lipid emulsions are a source of supplemental enteral nutrition for any patient in need thereof, including preterm infants.
A23D 7/005 - Compositions à base d'huiles ou de graisses comestibles, contenant une phase aqueuse, p.ex. margarines caractérisées par des ingrédients autres que des triglycérides d'acides gras
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
A tube feeding composition includes from about 20 wt% to about 40 wt% of fruit and vegetable, at least 3 wt% of whole grain, a source of protein, a source of carbohydrate, and a fat. The tube feeding composition has a desirable viscosity profile for tube feeding applications and may be manufactured using at least two homogenization steps.
The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
94.
METHODS FOR AIDING IN THE DIAGNOSIS AND EVALUATION OF A SUBJECT WHO HAS SUSTAINED AN ORTHOPEDIC INJURY AND THAT HAS OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD, SUCH AS MILD TRAUMATIC BRAIN INJURY (TBI), USING GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND/OR UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (UCH-L1)
Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
95.
METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING A COMBINATION OF GFAP AND UCH-L1
Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
96.
LIQUID NUTRITIONAL COMPOSITIONS INCLUDING GREEN TEA EXTRACT AND IRON
A sterilized liquid nutritional composition has an off-white color and a pH of from about 6 to 7.5 and comprises a source of protein, a source of fat, a source of carbohydrate, green tea extract comprising epigallocatechin gallate (EGCg), and an insoluble source of iron comprising at least one of ferric orthophosphate and ferric pyrophosphate. The liquid nutritional composition comprises, per 237 ml serving, from about 50 to 500 mg green tea extract and from about 6 to 60 mg ferric orthophosphate and/or ferric pyrophosphate, and has a Hunter L value not less than 60.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
97.
NUTRITIONAL TABLETS AND METHODS OF MAKING THE SAME
Nutritional tablets and methods of making nutritional tablets are provided. The nutritional tablets include a compressed nutritional powder that includes protein, carbohydrate, fat, and 0.15% to 6% by weight of a flow agent based on the weight of the nutritional tablet. The nutritional tablet has a hardness of no more than 14 N and a surface polarity of greater than 30.5%.
A23L 33/125 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Nutritional compositions for modulating or reducing inflammation in an individual in need. The nutritional compositions can include a rice protein hydrolysate having a minimum degree of hydrolysis of 15%, where at least 30% of the rice protein hydrolysate peptides are less than 1000 Da., and no more than 30% of the rice protein peptides are greater than 3000 Da.
Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
100.
METHODS FOR INCREASING GROWTH OF BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT
Disclosed are nutritional compositions including 2'-fucosyllactose (2'-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.
brevets
